2014 ACR/ARHP Annual Meeting

November 14-19, 2014. Boston, MA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 698

Grip Strength Identifies Increased Physical Disability in Women with Systemic Lupus Erythematosus
Abstract Number: 276

Growth during Tocilizumab Therapy for Polyarticular-Course Juvenile Idiopathic Arthritis: 2-Year Data from a Phase 3 Clinical Trial
Abstract Number: 622

Gut Microbiota Variations Correlate with Disease Activity in Spondyloarthritis (SpA) and Rheumatoid Arthritis (RA)
Abstract Number: 2895

Habitual Running Any Time in Life Is Not Detrimental and May be Protective of Symptomatic Knee Osteoarthritis: Data from the Osteoarthritis Initiative
Abstract Number: 2201

Haematological Complications in Rheumatic Diseases: Not Only Lymphomas
Abstract Number: 1014

Harpagide, a Low Molecular Weight Natural Product, Suppresses IL-1â-Induced IL-6 Expression By Blocking the Activation of p38 MAPK and Transcription Factors CEBPâ and AP-1 in Primary Human Osteoarthritis Chondrocytes
Abstract Number: 2228

Has MRI an Added Value over Serum Creatine Kinase Measurement in Myositis?
Abstract Number: 2652

Headache in Patients with Systemic Lupus Erythematosus Is Associated with Reduced Cerebral Grey Matter Volume, but not with Measures of Glial Activation, Anti-NR2-, or Anti-P Antibodies
Abstract Number: 2621

Health-Related Quality of Life in Patients with Systemic Lupus Erythematosus
Abstract Number: 1142

Healthcare Costs Associated with Serious Infections Among Biologic-Naïve Rheumatoid Arthritis Patients Initiating First-Line Biologic Treatment
Abstract Number: 866

Heart Rate Variability: An Inflammatory Biomarker in Systemic Lupus Erythematosus
Abstract Number: 1681

Heart Transplantation in 6 Patients with Systemic Sclerosis and a Primary Cardiac Involvement
Abstract Number: 647

Helminthes Derivative for Treating Lupus and Colitis in Mice Models
Abstract Number: 586

Helplessness in Coping Is Associated with Worse Patient Reported Outcomes Among Patients with Ankylosing Spondylitis: A Longitudinal Multi-Country Cohort Study
Abstract Number: 1027

Hematopoietic Cell Kinase (HCK) As a Novel Regulator of Fibroblast-like Synoviocyte Function in RA

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].